MPP2 and glioblastoma: For example, while a phase I study (NCT05353530) is designed to assess the safety and efficacy of IL-8 receptor-modified CD70 CAR T cell therapy in CD70+ glioblastoma, another phase I trial (NCT04214392) is studying the side effect and dose of CAR T cells with a chlorotoxin tumor targeting domain in patients with MPP2+ GBM [96,97].